20 marzo 2015
Hypermethylation – the epigenetic ability to turn down or turn off a bad gene implicated in 10 to 30 percent of patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD) – serves as a protective barrier inhibiting the development of these diseases, researchers have found. Their work may suggest a neuroprotective target for drug discovery efforts.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/K6m9BUn1XAI/150320180802.htm
